Decoy Therapeutics reports preclinical data backing once-weekly intranasal dosing for DCOY-CoV program
Bitget2026/09/29 11:32- Decoy Therapeutics disclosed preclinical pharmacokinetic results supporting once-weekly intranasal dosing for its lead DCOY-CoV program.
- The data were scheduled for presentation later on September 29 at the Boulder Peptide Symposium’s Peptide Showcase.
- Findings indicate a single dose could sustain protective drug exposure across upper airways and lungs for about a week.
- The program targets prevention or treatment of endemic human coronaviruses in high-risk patients, where no non-COVID options are approved.
- DCOY-CoV is expected to enter clinical trials in 2027, setting up a key valuation inflection point tied to first-in-human data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Australian Dollar: Neutral outlook inside tight range against US Dollar – UOB
Power Root buys back shares for MYR 147,891.13
Power Root bought back 134,300 ordinary shares on Oct. 7, 2026, paying MYR 147,891.13. Purchases were priced between MYR 1.08 and MYR 1.12; all shares were retained as treasury stock. Treasury shares rose to 16,051,800, representing 3.78% of issued shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Power Root Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3712895) on October 07, 2026, and is solely responsible for the information contained therein.
EPF Board trims IOI Corp stake, disposes 800,000 shares; holding at 18.651%
Malaysia’s EPF cut its stake in IOI Corp via the disposal of 800,000 ordinary shares on Oct. 2, 2026. EPF’s direct holding stood at 1,172,249,528 shares, equal to 18.65% of issued shares, following the transaction. The disclosure was dated Oct. 5, 2026, with the company receiving the notice on Oct. 7, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IOI Corporation Berhad published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3712867) on October 07, 2026, and is solely responsible for the information contained therein.
Elon Musk reportedly contacts TSMC, Intel CEO Pat Gelsinger quickly responds: Terafab collaboration continues
Intel (INTC.US) CEO Patrick Gelsinger stated that the company will continue its collaboration with Elon Musk on the Terafab project.
Crypto prices
More
